Meghan V. Joyce Sells 3,337 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Meghan V. Joyce sold 3,337 shares of Guardant Health stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $47.22, for a total value of $157,573.14. Following the completion of the sale, the director now owns 11,150 shares of the company's stock, valued at $526,503. The trade was a 23.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Guardant Health Stock Up 0.0%

NASDAQ GH traded up $0.01 on Monday, reaching $49.30. The company had a trading volume of 1,666,663 shares, compared to its average volume of 2,129,196. The stock has a market capitalization of $6.11 billion, a PE ratio of -13.85 and a beta of 1.37. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92. The firm's 50 day moving average price is $43.72 and its 200 day moving average price is $41.65.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The business had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm's revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.46) EPS. On average, research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Hedge Funds Weigh In On Guardant Health

Institutional investors have recently bought and sold shares of the business. Osterweis Capital Management Inc. bought a new position in shares of Guardant Health during the first quarter valued at approximately $12,634,000. Rhumbline Advisers raised its position in Guardant Health by 4.9% during the 1st quarter. Rhumbline Advisers now owns 175,432 shares of the company's stock valued at $7,473,000 after purchasing an additional 8,202 shares in the last quarter. Strs Ohio purchased a new stake in shares of Guardant Health in the 1st quarter worth $809,000. Intech Investment Management LLC raised its holdings in shares of Guardant Health by 37.3% in the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock valued at $2,564,000 after acquiring an additional 16,363 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Guardant Health by 6.3% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company's stock worth $118,302,000 after acquiring an additional 164,263 shares during the period. Institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. UBS Group lifted their price target on shares of Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research note on Thursday, May 1st. Canaccord Genuity Group lifted their target price on shares of Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Guggenheim reiterated a "buy" rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Piper Sandler restated an "overweight" rating and issued a $60.00 price target (up from $50.00) on shares of Guardant Health in a research note on Tuesday, May 6th. Finally, Raymond James reaffirmed an "outperform" rating and issued a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty-one analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health has a consensus rating of "Buy" and an average target price of $53.76.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.